William D. Figg

Also affiliated with National Cancer Institute, National Cancer Institute, National Institutes of Health Clinical Center, National Cancer Research Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

8in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 8 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.22486571

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Papers

Driven by 138 papers — median percentile 0. Top paper: “Selumetinib in Children with Inoperable Plexiform Neurofibromas”.

Selumetinib in Children with Inoperable Plexiform Neurofibromas

New England Journal of Medicine(2020)10.1056/nejmoa1912735

N/A

9.0DataRank · unranked

708 citations

Pamela L. Wolters, Eva Dombi, Andrea Baldwin, Patricia Whitcomb, Michael J. Fisher +24 more

Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress

Cancer Cell(2021)10.1016/j.ccell.2021.02.014

N/A

4.8DataRank · unranked

178 citations

Nobuyuki Takahashi, Vinodh N. Rajapakse, Xiaohu Zhang, Yilun Sun, Michele Ceribelli +36 more

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Journal of Clinical Oncology(2020)10.1200/jco.20.01652

N/A

3.5DataRank · unranked

138 citations

Rosa Nadal, Daniel M. Girardi, Scot A. Niglio, Lisa Ley, Lisa M. Cordes +30 more

Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30202-3

N/A

3.0DataRank · unranked

89 citations

Rosa Nadal, Yusuke Tomita, Nicole N. Davarpanah, Lisa M. Cordes, Seth M. Steinberg +27 more

A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma

The Oncologist(2022)10.1093/oncolo/oyab073

N/A

1.5DataRank · unranked

44 citations

Erica C. Pehrsson, Changqing Xie, Austin G. Duffy, Donna Mabry, Bradford J. Wood +10 more

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma

New England Journal of Medicine(2024)10.1056/nejmoa2401532

N/A

1.5DataRank · unranked

68 citations

Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Da Wei Huang, George W. Wright +31 more

Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2022-005640

N/A

1.4DataRank · unranked

72 citations

Changqing Xie, Yuta Myojin, Kelley Coffman, Donna Mabry Hrones, Sophie Wang +15 more

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma

JAMA Oncology(2021)10.1001/jamaoncol.2021.3971

N/A

1.3DataRank · unranked

45 citations

Elizabeth Hill, Alexander Dew, Candis Morrison, Joseph Roswarski, Neha Korde +29 more

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3726

N/A

1.1DataRank · unranked

24 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo Lara, Sumanta K. Pal +30 more

Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-20-0228

N/A

0.818DataRank · unranked

20 citations

Cindy H. Chau, Jonathan D. Strope, Alwin D. R. Huitema, Tristan M. Sissung, Douglas K. Price +2 more

A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2168

N/A

0.815DataRank · unranked

22 citations

R. Taylor Sundby, Mary Frances Wedekind, Fernanda I. Arnaldez, Jaydira Del Rivero, Lori Wiener +27 more

Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs

The FASEB Journal(2020)10.1096/fj.201903060rr

N/A

0.800DataRank · unranked

28 citations

Phoebe Huang, Emily Harris, Jonathan D. Strope, Christopher B. Mahony, Cindy H. Chau +3 more

A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide

The Oncologist(2022)10.1093/oncolo/oyac100

N/A

0.790DataRank · unranked

24 citations

Fatima Karzai, Marijo Bilušić, Lisa M. Cordes, Cindy H. Chau, Cody J. Peer +8 more

Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation

Blood Advances(2025)10.1182/bloodadvances.2024014879

N/A

0.783DataRank · unranked

24 citations

Dimana Dimitrova, Ruby Sabina, Ashley DeVries, Jeannine S. McCune, Meredith J. McAdams +17 more

COVID‐19 Clinical Diagnostics and Testing Technology

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy(2020)10.1002/phar.2439

N/A

0.749DataRank · unranked

146 citations

Jonathan D. Strope, William D. Figg, Cindy H. Chau

Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors

Cancer Chemotherapy and Pharmacology(2020)10.1007/s00280-020-04134-9

N/A

0.730DataRank · unranked

20 citations

Alwin D. R. Huitema, Thomas P. C. Dorlo, Cody J. Peer, Lisa M. Cordes, Linda Sciuto +6 more

Liquid biopsy epigenomic profiling for cancer subtyping

Nature Medicine(2023)10.1038/s41591-023-02605-z

N/A

0.722DataRank · unranked

122 citations

Ji-Heui Seo, Matthew P. Davidsohn, Brad Fortunato, Karl Semaan, Shahabbedin Sotudian +38 more

TMPRSS2: Potential Biomarker for COVID‐19 Outcomes

The Journal of Clinical Pharmacology(2020)10.1002/jcph.1641

N/A

0.681DataRank · unranked

93 citations

Cindy H. Chau, William D. Figg, Jonathan D. Strope

PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics

Seminars in Oncology(2023)10.1053/j.seminoncol.2023.09.005

N/A

0.665DataRank · unranked

83 citations

Oluwatobi Arisa, Cody J. Peer, Antonio Tito Fojo, William D. Figg, Yi Zeng

Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair–targeted therapies

Science Translational Medicine(2021)10.1126/scitranslmed.abc7488

N/A

0.646DataRank · unranked

73 citations

Nobuyuki Takahashi, Lőrinc Sándor Pongor, Vinodh N. Rajapakse, Manoj Tyagi, Xinyu Wen +20 more

Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy

The Prostate(2020)10.1002/pros.23948

N/A

0.629DataRank · unranked

13 citations

Samuel Pan, William D. Figg, Zoila A. Lopez‐Bujanda, Jonathan D. Strope, David H. Aggen +6 more

Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin

Cancer(2020)10.1002/cncr.33145

N/A

0.621DataRank · unranked

62 citations

Christine Alewine, Idrees Mian, Anna Spreafico, Lillian L. Siu, Carlos Gomez‐Roca +13 more

Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4730

N/A

0.617DataRank · unranked

60 citations

Ying Yuan, Debra A. Long Priel, Danielle Fink, Cody J. Peer, Tristan M. Sissung +30 more

DPYD Testing: Time to Put Patient Safety First

Journal of Clinical Oncology(2023)10.1200/jco.22.02364

N/A

0.561DataRank · unranked

41 citations

Susan E. Bates, Gabriel A. Brooks, William L. Dahut, Robert B. Diasio, Wafik S. El‐Deiry +17 more

Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0536

N/A

0.557DataRank · unranked

40 citations

Nobuyuki Takahashi, Cody J. Peer, Christophe E. Redon, Samantha Nichols, Rasa Vilimas +30 more

Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex

Nature Communications(2023)10.1038/s41467-023-39374-9

N/A

0.510DataRank · unranked

29 citations

Simone A. Baechler, Xiaohu Zhang, Suresh Kumar, Valentina M. Factor, Yasuhiro Arakawa +20 more

Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group

Journal of Clinical Oncology(2023)10.1200/jco.22.01777

N/A

0.507DataRank · unranked

10 citations

Gilbert Vézina, Mark Krailo, Linda Springer, Allen Buxton, Cody J. Peer +7 more

Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-0855

N/A

0.477DataRank · unranked

23 citations

Wei Zhang, Seth M. Steinberg, Darryl Nousome, Nicole Houston, Xiaolin Wu +22 more

Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management

Cancers(2021)10.3390/cancers13092154

N/A

0.477DataRank · unranked

23 citations

Keith T. Schmidt, Cindy H. Chau, William D. Figg, David Doan

VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008079

N/A

0.470DataRank · unranked

11 citations

Yuta Myojin, Cecilia Monge, Changqing Xie, Donna Mabry Hrones, Bradford J. Wood +7 more

The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1646

N/A

0.464DataRank · unranked

21 citations

Xiaolin Wan, Jacob S. Roth, David J. Liewehr, Nancy E. Sealover, William J.E. Frye +29 more

Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors

Pediatric Blood & Cancer(2021)10.1002/pbc.29282

N/A

0.461DataRank · unranked

10 citations

Brigitte C. Widemann, Pamela S. Hinds, Rochelle Bagatell, Suzanne Shusterman, Emily Stern +12 more

Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures

Molecular Cancer Research(2020)10.1158/1541-7786.mcr-20-0046

N/A

0.457DataRank · unranked

20 citations

Karol Szczepanek, Maxwell Lee, Howard H. Yang, Cody J. Peer, Jessica D. Kindrick +6 more

Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma

Cancer Medicine(2024)10.1002/cam4.6912

N/A

0.450DataRank · unranked

12 citations

Changqing Xie, Yuta Myojin, Kelley Coffman, Donna Mabry Hrones, Gagandeep Brar +12 more

Recent Advances in Bioanalytical Methods for Quantification and Pharmacokinetic Analyses of Antibody–Drug Conjugates

The AAPS Journal(2025)10.1208/s12248-025-01115-9

N/A

0.425DataRank · unranked

16 citations

Yi Zeng, Abdul-Azeez Lanihun, Oluwatobi Arisa, Jonathan Horner, William D. Figg +1 more

Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib

Cancer Chemotherapy and Pharmacology(2020)10.1007/s00280-020-04071-7

N/A

0.406DataRank · unranked

14 citations

Cody J. Peer, Arman Odabas, Cynthia Lester McCully, Rafael Cruz Garcia, William D. Figg +2 more

Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA)n Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?

International Journal of Molecular Sciences(2020)10.3390/ijms21030896

N/A

0.385DataRank · unranked

12 citations

Roberto H. Barbier, Douglas K. Price, Teri M. Plona, Kristen Pike, Stephanie D. Mellott +10 more

Genomic alterations and transcriptional phenotypes in circulating free DNA and matched metastatic tumor

Genome Medicine(2025)10.1186/s13073-025-01438-4

N/A

0.373DataRank · unranked

11 citations

Lőrinc Sándor Pongor, Shivam P. Agrawal, Mariya Shtumpf, Ankita Gurjar, Vinodh N. Rajapakse +13 more

Determination of the endogenous OATP1B biomarkers glycochenodeoxycholate-3-sulfate and chenodeoxycholate-24-glucuronide in human and mouse plasma by a validated UHPLC-MS/MS method

Journal of Chromatography B(2022)10.1016/j.jchromb.2022.123437

N/A

0.360DataRank · unranked

10 citations

Yang Li, Eric D. Eisenmann, William D. Figg, Sharyn D. Baker, Alex Sparreboom +2 more

Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-24-0225

N/A

0.345DataRank · unranked

9 citations

Christopher J. Ricketts, Laura S. Schmidt, Julia I. Medina, Keita Saito, Lilia Ileva +25 more

Case Report: Severe Toxicity in an African–American Patient Receiving FOLFOX Carrying Uncommon Allelic Variants in DPYD

Pharmacogenomics(2020)10.2217/pgs-2020-0120

N/A

0.345DataRank · unranked

9 citations

Lisa M. Cordes, Cody J. Peer, Shruti U. Gandhy, Jason M. Redman, Julius Strauss +2 more

Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity

Proceedings of the National Academy of Sciences(2024)10.1073/pnas.2413372121

N/A

0.330DataRank · unranked

8 citations

Frances A. Tosto, Xiaohu Zhang, Christopher Melani, Mark Roschewski, Erin Beck +13 more

A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.11552

N/A

0.312DataRank · unranked

7 citations

Kathryn Lurain, Anaida Widell, Priscila Gonçalves, Irene Ekwede, William D. Figg +9 more

PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.105

N/A

0.312DataRank · unranked

7 citations

Fatima Karzai, Jennifer L. Marté, Marijo Bilušić, Sheri McMahon, Julius Strauss +10 more

Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer

Nature Communications(2025)10.1038/s41467-025-64042-5

N/A

0.292DataRank · unranked

6 citations

Daniel Westaby, Ines Figueiredo, Alexis de Haven Brandon, Ana Padilha, Wei Yuan +53 more

Navigating the oncology drug discovery and development process with programmes supported by the National Institutes of Health

The Lancet Oncology(2024)10.1016/s1470-2045(24)00348-6

N/A

0.292DataRank · unranked

6 citations

Erica L. Beatson, Annieka Reno, Cindy H. Chau, Rosemarie Aurigemma, Patricia S. Steeg +2 more

Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling

Nature Communications(2025)10.1038/s41467-025-64509-5

N/A

0.269DataRank · unranked

5 citations

Nobuyuki Takahashi, Lenka Oplustil O’Connor, Christophe E. Redon, Chirayu Mohindroo, Linda Sciuto +8 more

Genomic Characterization of Preclinical Prostate Cancer Cell Line Models

International Journal of Molecular Sciences(2024)10.3390/ijms25116111

N/A

0.269DataRank · unranked

5 citations

Emily N. Risdon, Giulia C. Napoli, Douglas K. Price, Cindy H. Chau, William D. Figg +1 more

Biological Effects of Modifications of the Englerin A Glycolate

ACS Medicinal Chemistry Letters(2022)10.1021/acsmedchemlett.2c00258

N/A

0.269DataRank · unranked

5 citations

S. Alice Long, Rhone K. Akee, Gabriela Bermudez, Gregory Parsonage, Jonathan D. Strope +6 more

DNA Repair: ERCC1, Nucleotide Excision Repair, and Platinum Resistance

Cancer Drug Discovery and Development(2014)10.1007/978-1-4614-9135-4_18

N/A

0.269DataRank · unranked

5 citations

Teri L. Larkins, Cindy H. Chau, William D. Figg, Eddie Reed

Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma

Journal of Clinical Investigation(2026)10.1172/jci195725

N/A

0.241DataRank · unranked

4 citations

Karl Semaan, Jiao Li, Ze Zhang, Prathyusha Konda, Ananthan Sadagopan +27 more

The immunocytokine M9241 in the treatment of prostate cancer (PCa): Clinical and immune data from a phase 1 study.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.127

N/A

0.241DataRank · unranked

4 citations

Ravi A. Madan, Nicole J. Toney, Renee N. Donahue, Margaret E. Gatti‐Mays, Julius Strauss +12 more

Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.093

N/A

0.241DataRank · unranked

4 citations

Elias Bin Aris Chandran, Luke Meininger, Fatima Karzai, Marijo Bilušić, Jennifer L. Marté +15 more

A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps5096

N/A

0.208DataRank · unranked

3 citations

Marijo Bilušić, Fatima Karzai, Lisa M. Cordes, Julius Strauss, Houssein Abdul Sater +10 more

Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e17033

N/A

0.208DataRank · unranked

3 citations

Elias Bin Aris Chandran, Luke Meininger, Fatima Karzai, Marijo Bilušić, Jennifer L. Marté +15 more

Preclinical Evaluation of a Novel Series of Polyfluorinated Thalidomide Analogs in Drug-Resistant Multiple Myeloma

Biomolecules(2024)10.3390/biom14060725

N/A

0.208DataRank · unranked

3 citations

Matthew K. Collins, Cindy H. Chau, Hyoyoung Choo‐Wosoba, David Venzon, Christian Steinebach +6 more

Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3553

N/A

0.165DataRank · unranked

2 citations

Mehwish Ahmad, Yunkai Yu, Akira Yuno, Min-Jung Lee, Cody J. Peer +8 more

Determination of metarrestin (ML-246) in human plasma for a first-in-human clinical pharmacokinetic application by a simple and efficient uHPLC-MS/MS assay

Journal of Chromatography B(2023)10.1016/j.jchromb.2023.123738

N/A

0.165DataRank · unranked

2 citations

Sara Zimmerman, Annieka Reno, Natalia Corvalan Cabanas, Oluwatobi Arisa, Rushikesh Sable +3 more

ABCG2, THE BREAST CANCER RESISTANCE PROTEIN (BCRP)

Drug Transporters(2022)10.1002/9781119739883.ch12

N/A

0.165DataRank · unranked

2 citations

Sabrina Lusvarghi, Cindy H. Chau, Agnes Basseville, William D. Figg, Suresh V. Ambudkar +2 more

A rebrand for proteasome inhibition in solid tumors via continuous hepatic artery infusion

JCI Insight(2025)10.1172/jci.insight.199200

N/A

0.104DataRank · unranked

1 citations

Jack H. Victory, Priyanka P. Desai, Lindsay R. Friedman, H. Stepp, Robynne Ashe +14 more

Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma

Research Square(2024)10.21203/rs.3.rs-4406606/v1

N/A

0.104DataRank · unranked

1 citations

Hani Hassoun, Neha Korde, Kylee Maclachlan, Sham Mailankody, Dhwani Patel +26 more

Evaluating biomarkers in metastatic castration-resistant prostate cancer patients treated with enzalutamide: PSA, circulating tumor cell counts, AR-V7 status and radiographic progression.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e17569

N/A

0.104DataRank · unranked

1 citations

Fatima Karzai, Jennifer L. Marté, Marijo Bilušić, Sheri McMahon, Julius Strauss +13 more

A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4571

N/A

0.104DataRank · unranked

1 citations

Scot A. Niglio, Elias Chandran, Giovanni Maria Iannantuono, Salah Boudjadi, Rouf Banday +15 more

Further Personalizing Medicine in Immune Disorders: Genomic Findings and Hematopoietic Cell Transplantation Survival

Transplantation(2025)10.1097/tp.0000000000005504

N/A

0.104DataRank · unranked

1 citations

Sarah A. Bannon, Jia Yan, Rajarshi Ghosh, Ekaterina Damskey, Breanna Beers +41 more

PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e17046

N/A

0.104DataRank · unranked

1 citations

Shruti U. Gandhy, Fatima Karzai, Munjid Al Harthy, Gang Chen, Marijo Bilušić +15 more

Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e17044

N/A

0.104DataRank · unranked

1 citations

Shruti U. Gandhy, Fatima Karzai, Marijo Bilušić, Lisa M. Cordes, Helen Owens +8 more

Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro

International Journal of Nanomedicine(2020)10.2147/ijn.s234112

N/A

0DataRank · unranked

24 citations

Md. Nazir Hossen, Priya Shankarappa, Cody J. Peer, William D. Figg, J. David Robertson +3 more

Bridging Health Disparities: a Genomics and Transcriptomics Analysis by Race in Prostate Cancer

Journal of Racial and Ethnic Health Disparities(2023)10.1007/s40615-023-01534-4

N/A

0DataRank · unranked

7 citations

Erica L. Beatson, Seth M. Steinberg, Cindy H. Chau, Douglas K. Price, William D. Figg +1 more

Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide

European Urology Oncology(2023)10.1016/j.euo.2023.09.010

N/A

0DataRank · unranked

3 citations

Fatima Karzai, Marijo Bilušić, Sheri McMahon, Lisa M. Cordes, Jennifer L. Marté +12 more

Targeting the metastatic niche: Single-cell lineage tracing in prime time

iScience(2023)10.1016/j.isci.2023.106174

N/A

0DataRank · unranked

4 citations

Giulia C. Napoli, Cindy H. Chau, Douglas K. Price, William D. Figg, Elijah Richard Sommer

Inherited risk for prostate cancer (PCa): Following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.390

N/A

0DataRank · unranked

1 citations

Barış Türkbey, Peter L. Choyke, Katherine Lee-Wisdom, Yolanda McKinney, Robert Sidlow +10 more

Analysis of systemic immune changes in patients with advanced cancer treated with immunotoxin LMB-100 and tofacitinib.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e15017

N/A

0DataRank · unranked

1 citations

Cody J. Peer, Yunkai Yu, Min-Jung Lee, Sunmin Lee, Shraddha Rastogi +10 more

Effects of docetaxel on circulating immune cell subsets and association with outcomes in metastatic castration-sensitive prostate cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.207

N/A

0DataRank · unranked

0 citations

Meghali Goswami, Renee N. Donahue, Mohammad Atiq, Fatima Karzai, Marijo Bilušić +13 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.22486571

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Figshare(2023)10.1158/1078-0432.22486556.v1

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas

(2023)10.1158/1078-0432.c.6530789

Top 100%

0DataRank

Top 100%0 citations

Ying Yuan, Debra A. Long Priel, Danielle Fink, Cody J. Peer, Tristan M. Sissung +30 more

Data from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas

(2023)10.1158/1078-0432.c.6530789.v1

Top 100%

0DataRank

Top 100%0 citations

Ying Yuan, Debra A. Long Priel, Danielle Fink, Cody J. Peer, Tristan M. Sissung +30 more

Data from A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer

(2023)10.1158/1078-0432.c.6519969

N/A

0DataRank · unranked

0 citations

Deborah Draper, Clara C. Chen, Robert W. Robey, William D. Figg, Richard Piekarz +8 more

Data from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.c.6532346.v1

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Data from Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma

(2023)10.1158/1535-7163.c.6543340.v1

N/A

0DataRank · unranked

0 citations

Vanessa Del Pozo, Marielle E. Yohe, Craig M. Goodwin, Terry J. Shackleford, Long Wang +11 more

Data from Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma

(2023)10.1158/1535-7163.c.6543340

N/A

0DataRank · unranked

0 citations

Vanessa Del Pozo, Marielle E. Yohe, Craig M. Goodwin, Terry J. Shackleford, Long Wang +11 more

Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics

Science Translational Medicine(2021)10.1126/scitranslmed.abd8077

N/A

0DataRank · unranked

113 citations

Catriona P. Harkins, Nicole H. Schwardt, J. Portillo, NISC Comparative Sequencing Program, Matthew Zimmerman +10 more

A multi-center natural history study of precision-based genomics in prostate cancer (PC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5121

N/A

0DataRank · unranked

0 citations

Joaquı́n Mateo, Wassim Abida, Rana R. McKay, Bruce Montgomery, Rahul Aggarwal +5 more

Impact of fludarabine exposure on the depth and duration of lymphopenia and CAR T-cell outcomes.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.10033

N/A

0DataRank · unranked

0 citations

Bonnie Yates, Nicole Binder, Haneen Shalabi, Cody J. Peer, William D. Figg +3 more

Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate, in patients (pts) with advanced prostate cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5117

N/A

0DataRank · unranked

0 citations

Jose W. Avitia, James L. Bailen, Luke T. Nordquist, William J. Richardson, Cody J. Peer +8 more

A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5101

N/A

0DataRank · unranked

0 citations

Liza Lindenberg, Esther Mena Gonzalez, Barış Türkbey, Fatima Karzai, Megan Hausler +8 more

Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma

Cancer Chemotherapy and Pharmacology(2020)10.1007/s00280-019-04021-y

N/A

0DataRank · unranked

17 citations

Cynthia McCully, Arman Odabas, Rafael Pereira da Cruz, Cody J. Peer, William D. Figg +2 more

Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs

Molecules(2020)10.3390/molecules25235683

N/A

0DataRank · unranked

23 citations

Shaunna Beedie, Cindy H. Chau, Matthew K. Collins, Suzana Markolovic, Weiming Luo +8 more

Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman disease

Blood(2020)10.1182/blood.2019004602

N/A

0DataRank · unranked

51 citations

Kathryn Lurain, Cody J. Peer, Anna Serquiña, Victoria Wang, Anaida Widell +10 more

Small-molecule disruption of androgen receptor–dependent chromatin clusters

Proceedings of the National Academy of Sciences(2024)10.1073/pnas.2406239121

N/A

0DataRank · unranked

4 citations

EK Novak, Subhashish Tapadar, Bocheng Wu, Jonathan D. Strope, Yaw Asante +25 more

Distinct uptake and elimination profiles for trastuzumab, human IgG, and biocytin-TMR in experimental HER2+ brain metastases of breast cancer

Neuro-Oncology(2024)10.1093/neuonc/noae025

N/A

0DataRank · unranked

4 citations

Andy D. Tran, Monika A. Chung, Natalie N. Chung, Brunilde Gril, Christina M. Robinson +8 more

Systemic Treatment with the Janus Kinase Inhibitor Baricitinib in Ocular Chronic Graft-versus-Host Disease

Ophthalmology Science(2024)10.1016/j.xops.2024.100627

N/A

0DataRank · unranked

4 citations

Noa G. Holtzman, Aaron T. Zhao, Chantal Cousineau-Krieger, Susan Vitale, Edmond J. FitzGibbon +11 more

Revisiting the antiangiogenic mechanisms of fluorinated thalidomide derivatives

Bioorganic & Medicinal Chemistry Letters(2024)10.1016/j.bmcl.2024.129858

N/A

0DataRank · unranked

4 citations

Rabea Voget, Feiteng Lu, Kathleen M. Garchitorena, Yuen Lam Dora Ng, Cindy H. Chau +5 more

Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic breast cancer the LEANORA study

npj Breast Cancer(2024)10.1038/s41523-024-00692-w

N/A

0DataRank · unranked

1 citations

Dylan M. Smith, Cody Peer, Tristan M. Sissung, Keith T. Schmidt, Ming Tan +16 more

77P Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer

ESMO Open(2024)10.1016/j.esmoop.2024.103818

N/A

0DataRank · unranked

0 citations

D. Westaby, Ines Figueiredo, A. De Haven Brandon, Ana Padilha, W. Yuan +15 more

Treatment with novel topoisomerase inhibitors in Ewing sarcoma models reveals heterogeneity of tumor response

Frontiers in Cell and Developmental Biology(2024)10.3389/fcell.2024.1462840

N/A

0DataRank · unranked

0 citations

Ludmila Szabova, Victor J. Collins, Melanie B. Gordon, Kristine Johnson, Deborah B. Householder +15 more

Are sex discordant outcomes in COVID-19 related to sex hormones?

Seminars in Oncology(2020)10.1053/j.seminoncol.2020.06.002

N/A

0DataRank · unranked

60 citations

Cindy H. Chau, William D. Figg, Jonathan D. Strope

PARP Inhibitors and Prostate Cancer: To Infinity and BeyondBRCA

The Oncologist(2020)10.1634/theoncologist.2020-0697

N/A

0DataRank · unranked

97 citations

Cindy H. Chau, Douglas K. Price, Oliver Sartor, William D. Figg, Emily N. Risdon

Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING‐Associated Vasculopathy with Onset in Infancy Refractory to JAK Inhibitor and Dazukibart Therapy

Arthritis & Rheumatology(2025)10.1002/art.43145

N/A

0DataRank · unranked

14 citations

Bjoern Buehring, Adriana A. de Jesus, Sachin Gaurav, Andre Rastegar, Alexi Baumgardner +9 more

Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Cancer Research Communications(2025)10.1158/2767-9764.crc-25-0096

N/A

0DataRank · unranked

4 citations

Andres F. Leon, Erica L. Beatson, Jessica D. Kindrick, Kinjal Bhadresha, Xiaohu Zhang +15 more

Altering the gut microbiome and tumor microenvironment in advanced liver cancer: A phase II study of nivolumab, tadalafil and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers

Cancer Letters(2025)10.1016/j.canlet.2025.217975

N/A

0DataRank · unranked

3 citations

Joy Awosika, Cecilia Monge, Kelley Coffman, Changqing Xie, Nebojša Skorupan +13 more

Monoterpenoid fluorophthalimide IMiDs that lack human cereblon binding: synthesis and anti-proliferative, anti-angiogenic and anti-inflammatory activities

Biochemical and Biophysical Research Communications(2025)10.1016/j.bbrc.2025.152428

N/A

0DataRank · unranked

2 citations

Kathleen M. Garchitorena, David Tweedie, Cindy H. Chau, Chirag Patel, Maxime A. Siegler +7 more

Detection and monitoring of translocation renal cell carcinoma via plasma cell-free epigenomic profiling

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.08.31.673338

N/A

0DataRank · unranked

1 citations

Karl Semaan, Jiao Li, Ananthan Sadagopan, John Canniff, Noa Phillips +27 more

Radium 223 without androgen deprivation therapy (ADT) in patients (Pts) with biochemically recurrent prostate cancer (BCR) and PET findings in the bones.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.5_suppl.180

N/A

0DataRank · unranked

0 citations

Fatima Karzai, Philip M. Arlen, Clara Chen, Esther Mena, Liza Lindenberg +11 more

Vaping and Cancer Metastasis: Novel Preclinical Insights and Results from the All of Us Research Program

The Oncologist(2025)10.1093/oncolo/oyaf190

N/A

0DataRank · unranked

0 citations

Cindy H. Chau, Douglas K. Price, William D. Figg, Dhruv G Pillai

A Phase 0 Window of Opportunity Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Patients with Recurrent Gliomas

medRxiv(2025)10.1101/2025.08.18.25333496

N/A

0DataRank · unranked

0 citations

Erin Walker, Lisa Boris, Jennifer Reyes, Kelly Fernandez, Kathleen Wall +5 more

Sudden death and asymptomatic arrhythmia in chronic lymphocytic leukemia patients treated with ibrutinib

Heart Rhythm(2025)10.1016/j.hrthm.2025.10.014

N/A

0DataRank · unranked

0 citations

Andy Itsara, Mark C. Haigney, Douglas R. Rosing, Inhye E. Ahn, Cody Peer +7 more

Final results from a phase 1 trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced/metastatic genitourinary tumors

Research Square(2023)10.21203/rs.3.rs-2924051/v1

N/A

0DataRank · unranked

0 citations

Scot A. Niglio, Rosa Nadal, Andre R. Kydd, Nicholas I. Simon, Lisa Ley +36 more

Resistance to second-generation androgen receptor antagonists in prostate cancer

Nature Reviews Urology(2021)10.1038/s41585-021-00438-4

N/A

0DataRank · unranked

128 citations

Alwin D. R. Huitema, Cindy H. Chau, William D. Figg, Keith T. Schmidt

Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation

The Journal of Clinical Pharmacology(2021)10.1002/jcph.1984

N/A

0DataRank · unranked

35 citations

Brian L. Heiss, Daniel A. Goldstein, Jennifer C. Goodell, William D. Figg, Mark J. Ratain +1 more

Development and validation of a simple, selective, and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma

Journal of Chromatography B(2021)10.1016/j.jchromb.2021.122641

N/A

0DataRank · unranked

34 citations

Jennifer C. Goodell, Priya Shankarappa, Sara Zimmerman, Tyler Yin, Cody J. Peer +2 more

Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-21-0194

N/A

0DataRank · unranked

25 citations

Vanessa Del Pozo, Marielle E. Yohe, Craig M. Goodwin, Terry J. Shackleford, Long Wang +11 more

Adenosine A2A Receptor Activation Enhances Blood–Tumor Barrier Permeability in a Rodent Glioma Model

Molecular Cancer Research(2021)10.1158/1541-7786.mcr-19-0995

N/A

0DataRank · unranked

20 citations

Monica Manglani, DreeAnna Morris, Brandon Foster, Matthew McCord, Hua Song +15 more

Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial

Endocrine Related Cancer(2021)10.1530/erc-21-0107

N/A

0DataRank · unranked

17 citations

Cathee Till, Douglas K Price, Phyllis J Goodman, Marian L Neuhouser, Michael N Pollak +3 more

Ibrutinib’s off-target mechanism: cause for dose optimization

Cancer Biology & Therapy(2021)10.1080/15384047.2021.1980313

N/A

0DataRank · unranked

13 citations

Cody J. Peer, William D. Figg, Sara Zimmerman

Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in persons with pancreatobiliary cancer or other mesothelin expressing solid tumors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.tps452

N/A

0DataRank · unranked

5 citations

Mehwish Ahmad, Seth M. Steinberg, Cody J. Peer, William D. Figg, David J. FitzGerald +4 more

Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreatobiliary cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3051

N/A

0DataRank · unranked

4 citations

Mehwish Ahmad, Guillaume Joe Pegna, Cody J. Peer, Jane B. Trepel, Min-Jung Lee +9 more

A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps4599

N/A

0DataRank · unranked

4 citations

Daniel M. Girardi, Lisa M. Cordes, Lisa Ley, Marissa Mallek, Olena Sierra Ortiz +15 more

Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT

Cancer Biology & Therapy(2020)10.1080/15384047.2020.1796195

N/A

0DataRank · unranked

1 citations

Keith T. Schmidt, Douglas K. Price, William D. Figg, Whitney Handy

Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer

Cancer Biology & Therapy(2020)10.1080/15384047.2020.1809913

N/A

0DataRank · unranked

2 citations

Ravi A. Madan, William D. Figg, Vincent Chau

Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition

ACS Medicinal Chemistry Letters(2020)10.1021/acsmedchemlett.0c00186

N/A

0DataRank · unranked

3 citations

Jean‐Simon Suppo, Sarka Tumova, Jonathan D. Strope, Fernando Bravo, Melody Moy +8 more

Pharmacogenomics with red cells: a model to study protein variants of drug transporter genes

Vox Sanguinis(2020)10.1111/vox.12999

N/A

0DataRank · unranked

5 citations

Kshitij Srivastava, Tristan M. Sissung, Barry R. Goldspiel, William D. Figg, Willy A. Flegel

Quantitation of the next-generation imipridone ONC206 in human plasma by a simple and sensitive UPLC-MS/MS assay for clinical pharmacokinetic application

Journal of Pharmaceutical and Biomedical Analysis(2022)10.1016/j.jpba.2022.114685

N/A

0DataRank · unranked

7 citations

Sara Zimmerman, Cody J. Peer, Varun V. Prabhu, Tyler Yin, William J. Richardson +7 more

Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs

Frontiers in Veterinary Science(2022)10.3389/fvets.2022.1056408

N/A

0DataRank · unranked

8 citations

Cody J. Peer, William J. Richardson, Stephen M. Hewitt, William D. Figg, R. Mark Simpson +1 more

A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities

Pharmaceutics(2022)10.3390/pharmaceutics14091933

N/A

0DataRank · unranked

7 citations

Yan Jin, Hanieh Taheri, Keith T. Schmidt, Alice A. Gibson, Stefan A.J. Buck +7 more

Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted

Cancers(2022)10.3390/cancers14051131

N/A

0DataRank · unranked

4 citations

William D. Figg, Tristan M. Sissung

Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome

Cancer Biology & Therapy(2022)10.1080/15384047.2022.2033059

N/A

0DataRank · unranked

6 citations

Cindy H. Chau, Douglas K. Price, William D. Figg, Kristi Y. Lee

Cardiac toxicity in a pilot study of duvelisib and ibrutinib combination therapy for chronic lymphocytic leukaemia

British Journal of Haematology(2022)10.1111/bjh.18558

N/A

0DataRank · unranked

2 citations

Douglas R. Rosing, Mark C. Haigney, Cody J. Peer, William D. Figg, Adrian Wiestner +2 more

Self-reactive, innate-like T cells enhance cytotoxicity and immunosurveillance

Trends in cancer(2022)10.1016/j.trecan.2022.05.003

N/A

0DataRank · unranked

1 citations

Cindy H. Chau, William D. Figg, Blaire E. Barton

Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.130

N/A

0DataRank · unranked

3 citations

Mohammad Atiq, Renee N. Donahue, Fatima Karzai, Marijo Bilušić, Jennifer L. Marté +11 more

Commentary: Electronic Nicotine Delivery Systems

Family & Community Health(2022)10.1097/fch.0000000000000324

N/A

0DataRank · unranked

0 citations

William D. Figg, Tristan M. Sissung

Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma

Molecular Cancer Therapeutics(2020)10.1158/1535-7163.mct-19-0858

N/A

0DataRank · unranked

30 citations

Shelley Hoover, Cody J. Peer, Jennifer E. Dwyer, Hibret A. Adissu, Priya Shankarappa +6 more

Opportunities for using in silico‐based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors

British Journal of Clinical Pharmacology(2020)10.1111/bcp.14369

N/A

0DataRank · unranked

35 citations

Daniel A. Goldstein, Jennifer C. Goodell, Ryan Nguyen, William D. Figg, Mark J. Ratain +1 more

Inhibition of p38α MAPK restores neuronal p38γ MAPK and ameliorates synaptic degeneration in a mouse model of DLB/PD

Science Translational Medicine(2023)10.1126/scitranslmed.abq6089

N/A

0DataRank · unranked

40 citations

Changyoun Kim, Somin Kwon, Marcell Szabo, Liam Horan-Portelance, Cody J. Peer +10 more

Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer

British Journal of Urology(2020)10.1111/bju.15227

N/A

0DataRank · unranked

13 citations

Fatima Karzai, Munjid Al Harthy, Daniel P. Petrylak, Joseph W. Kim, Philip M. Arlen +22 more

Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment

Clinical Genitourinary Cancer(2020)10.1016/j.clgc.2019.11.002

N/A

0DataRank · unranked

17 citations

Keith T. Schmidt, Fatima Karzai, Cody J. Peer, Lisa M. Cordes, Cindy H. Chau +8 more

In Silico Re‐Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure–Response Simulation

The Journal of Clinical Pharmacology(2023)10.1002/jcph.2203

N/A

0DataRank · unranked

14 citations

Keith T. Schmidt, Oluwatobi Arisa, William J. Richardson, Koosha Paydary, Daniel A. Goldstein +4 more

Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma

Cancers(2023)10.3390/cancers15164034

N/A

0DataRank · unranked

13 citations

Adam Cheuk, Kristine A. Isanogle, Christina M. Robinson, Xiaohu Zhang, Michele Ceribelli +22 more

William D. Figg

Indexed papers

Top data-sharing exemplar

Papers